clinical trial · NCT06732245
Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
Biomed Industries, Inc.·phase2·not yet recruiting·n = 224
Obesity and OverweightNA-931TirzepatideTirzepatideNA-931NA-931NA-931NA-931 150 mg + no TirzepatideNA-931
brief summary
A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
started
Aug 15, 2026
primary completion
Aug 15, 2027
completion
Dec 15, 2027
last updated
Mar 27, 2026
detailed description
This Phase 2 study investigates if NA-931 in addition to Tirzepatide can demonstrate synergic effects by enhancing efficacy and reducing adverse events including preserve/increase muscle mass in the presence of weight and/or fat mass loss.
official title
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol